Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Open in API
Filings indexed 985 across all filing types
Latest filing 2017-06-08 Major Shareholding Noti…
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2017
Major Shareholding Notification
2017-06-08 English
10-Q
Interim / Quarterly Report Q1 2017
2017-05-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2017, reporting the company's financial results for the quarter ended March 31, 2017. It includes a press release as an exhibit announcing the first quarter results. The document is relatively short (3896 characters) and primarily serves as a current report announcing quarterly financial results rather than containing detailed financial statements or comprehensive analysis. This matches the description of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only. Therefore, the appropriate classification is ER.
2017-05-09 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about the Annual Meeting, voting instructions, director nominations, auditor ratification, and executive compensation advisory vote. The presence of detailed proxy materials and voting proposals aligns with the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors. The document is not the full proxy statement itself but definitive additional materials related to it, which still fall under the DEF 14A category. Therefore, the correct classification is DEF 14A.
2017-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2017-04-26 English
FORM 4 -
Director's Dealing
2017-04-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.